Last reviewed · How we verify
[14C]enpatoran microdose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C]enpatoran microdose ([14C]enpatoran microdose) — Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C]enpatoran microdose TARGET | [14C]enpatoran microdose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C]enpatoran microdose CI watch — RSS
- [14C]enpatoran microdose CI watch — Atom
- [14C]enpatoran microdose CI watch — JSON
- [14C]enpatoran microdose alone — RSS
Cite this brief
Drug Landscape (2026). [14C]enpatoran microdose — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-enpatoran-microdose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing